Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study / Feng-E Jiang ... [et al.]. Neoplasma Vol. 68, no. 4 (2021), s. 861-866